Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
60
ICCC Quote, Financials, Valuation and Earnings
Last price:
$6.57
Seasonality move
:
1.91%
Day range:
$6.43 - $6.75
52-week range:
$4.28 - $7.60
Dividend yield:
0%
P/E ratio:
25.61x
P/S ratio:
2.15x
P/B ratio:
2.01x
Volume:
20.1K
Avg. volume:
25K
1-year change:
22.1%
Market cap:
$60M
Revenue:
$26.5M
EPS (TTM):
$0.26
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, ImmuCell Corp. has 111.16% upside to fair value with a price target of -- per share.
ICCC vs. S&P 500
-
Over the past 5 trading days, ImmuCell Corp. has overperformed the S&P 500 by 11.18% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ImmuCell Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ImmuCell Corp. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ImmuCell Corp. reported revenues of $5.5M.
Earnings Growth
-
ImmuCell Corp. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter ImmuCell Corp. reported earnings per share of -$0.02.
Enterprise value:
69.7M
EV / Invested capital:
--
Price / LTM sales:
2.15x
EV / EBIT:
29.92x
EV / Revenue:
2.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
97.43x
Price / Operating cash flow:
83.40x
Enterprise value / EBITDA:
13.83x
Gross Profit (TTM):
$11.4M
Return On Assets:
5.11%
Net Income Margin (TTM):
8.37%
Return On Equity:
8.15%
Return On Invested Capital:
5.39%
Operating Margin:
0.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $16.3M | $23.8M | $27.8M | $6M | $5.5M | |
| Gross Profit | $3.2M | $6.4M | $11.4M | $1.6M | $2.4M | |
| Operating Income | -$6.4M | -$3.3M | $2.3M | -$574.9K | $20.1K | |
| EBITDA | -$3.7M | -$566.2K | $5M | $100.2K | $699.2K | |
| Diluted EPS | -$0.81 | -$0.49 | $0.26 | -$0.09 | -$0.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16.1M | $16.4M | $12M | $13.9M | $16.8M | |
| Total Assets | $44.2M | $46.4M | $44.5M | $44.4M | $45.7M | |
| Current Liabilities | $2.2M | $2.7M | $3.3M | $4.5M | $4M | |
| Total Liabilities | $11.8M | $14.4M | $18.5M | $18M | $15.9M | |
| Total Equity | $32.5M | $32M | $26M | $26.4M | $29.8M | |
| Total Debt | $10.4M | $12.7M | $16.6M | $15.1M | $13.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.2M | -$362.1K | $2M | -$639.3K | -$1.2M | |
| Cash From Investing | -$3.4M | -$231.2K | -$1.2M | -$88.4K | -$592K | |
| Cash From Financing | $1.8M | $2.4M | -$668.9K | $3.2M | -$337.7K | |
| Free Cash Flow | -$8.6M | -$712.9K | $715.3K | -$727.7K | -$1.8M | |
ICCC
Sector
Market Cap
$60M
$24.1M
Price % of 52-Week High
87.24%
49.1%
Dividend Yield
0%
0%
Shareholder Yield
-0.63%
-1.67%
1-Year Price Total Return
22.1%
-21.71%
Beta (5-Year)
0.300
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.21
200-day SMA
Buy
Level
$6.12
Bollinger Bands (100)
Buy
Level
5.49 - 6.57
Chaikin Money Flow
Sell
Level
-4M
20-day SMA
Buy
Level
$6.35
Relative Strength Index (RSI14)
Buy
Level
59.31
ADX Line
Buy
Level
23.05
Williams %R
Sell
Level
-12
50-day SMA
Buy
Level
$6.07
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
7.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8886)
Buy
CA Score
(Annual)
Level (0.0184)
Buy
Beneish M-Score
(Annual)
Level (-2.3195)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.8775)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.
Stock Forecast FAQ
In the current month, ICCC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ICCC average analyst price target in the past 3 months is --.
-
Where Will ImmuCell Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ImmuCell Corp. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About ImmuCell Corp.?
Analysts are divided on their view about ImmuCell Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ImmuCell Corp. is a Sell and believe this share price will drop from its current level to --.
-
What Is ImmuCell Corp.'s Price Target?
The price target for ImmuCell Corp. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ICCC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ImmuCell Corp. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ICCC?
You can purchase shares of ImmuCell Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ImmuCell Corp. shares.
-
What Is The ImmuCell Corp. Share Price Today?
ImmuCell Corp. was last trading at $6.57 per share. This represents the most recent stock quote for ImmuCell Corp.. Yesterday, ImmuCell Corp. closed at $6.63 per share.
-
How To Buy ImmuCell Corp. Stock Online?
In order to purchase ImmuCell Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ICCC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ICCC
Sector
P/E ratio
25.61x
23.23x
PEG ratio
--
-0.01x
P/B ratio
2.01x
1.75x
Price / LTM sales
2.15x
1.50x
Growth Metrics
ICCC
Sector
Revenue growth
-8.41%
3.24%
Earnings growth
82.07%
10.12%
Revenue (5-year growth)
14.06%
6.27%
Earnings forecast
--
-$0.19
Profitability
ICCC
Sector
Profitability FY 2024
$7.9M
$2.7M
Return on invested capital
5.39%
-33.65%
Return on assets
5.11%
-29.68%
Return on equity
8.15%
-38.98%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
12
Balance Sheet
ICCC
Sector
Total cash
$3.9M
$25M
Short term investments
--
$23.9M
Total assets
$45.1M
$72.5M
Long term debt
$13.5M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
48
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 29x
Alerts
Buy
73
NKTR alert for Feb 11
Nektar Therapeutics [NKTR] is up 13.71% over the past day.
Buy
53
ICHR alert for Feb 11
Ichor Holdings Ltd. [ICHR] is up 0.2% over the past day.
Sell
26
MEDP alert for Feb 11
Medpace Holdings, Inc. [MEDP] is down 3.85% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
